Greg Zante, Chief Financial Officer at Viking Therapeutics, Inc. (VKTX), sold 115,322 shares at $32.30 ($3.8M) on 2026-01-05, disclosed to the SEC on 2026-01-05.
Seasonal sale ($3.8M) by Chief Financial Officer — this insider has traded VKTX in January in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $32.09 | 1,500 | $48K | 1.3% |
| 2 | $32.09 | 1,500 | $48K | 1.3% |
| 3 | $32.30 | 31,961 | $1.0M | 27.2% |
| 4 | $32.30 | 31,961 | $1.0M | 27.2% |
| 5 | $33.38 | 13,900 | $464K | 12.2% |
| 6 | $33.38 | 13,900 |
| $464K |
| 12.2% |
| 7 | $34.24 | 10,300 | $353K | 9.3% |
| 8 | $34.24 | 10,300 | $353K | 9.3% |
| Total | $32.90 avg | 115,322 | $3.8M | 100% |
| Filing → |
| VKTX | SELL | 2025-07-03 | $237K | — | Filing → |
| VKTX | SELL | 2025-01-06 | $4.1M | — | Filing → |
| VKTX | SELL | 2024-10-28 | $19.7M | — | Filing → |